MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
MediWound reported Q1 2026 revenue of $1.5 million, a 63% decline year-over-year, driven by timing of BARDA revenues and postponed shipments due to regional conflict. The company posted a net loss of $3.0 million ($0.23 per share) and an operating loss of $8.0 million, with R&D expenses rising to $5.2 million due to the EscharEx Phase III trial. Despite the weak quarter, MediWound reaffirmed its full-year 2026 revenue guidance of $24-26 million, citing expected government-related revenue in H2 2026 and a new $197M BARDA contract awarded to partner Vericel.
Key figures
- Revenue
- 1475000
- Guidance
- FY26 revenue $24M-$26M (reaffirmed)
- Revenue Yoy
- -62.7%
- Net loss
- 2952000
- Rd expense
- 5185000
- Gross margin
- 21.9%
- Gross profit
- 323000
- Operating loss
- 7980000
- Adj ebitda loss
- 6958000
- Barda contract value
- 197000000
- Cash and equivalents
- 44646000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.